My Approach to Investing in CAR-T Drug Development: Cryoport (CYRX, Buy, $5.67)); Kite (KITE, Neutral, $104.34); Juno (JUNO, Neutral, $27.87), Novartis, (NVS, No opinion, $84.85)Wednesday, July 19, 2017 · 9:40 am |
|
Thoughts on the Probable Launches of the First CAR-T Drugs; Cryoport is a Novel Way to Invest In This: Cryoport (CYRX, Buy, $2.36) and Kite (KITE, Neutral, $83.37)Thursday, April 27, 2017 · 8:39 am |
|
Kite Pharma: Novartis and Kite File for Regulatory Approval of Their CAR-T Products; I Do Not Believe That KITE Has a Meaningful First Mover Advantage (KITE, Neutral, $82.19)Monday, April 3, 2017 · 8:56 am |
|
Kite Pharma: Analysis of Six Month Data from ZUMA-1 That Led to 40% Price Increase (KITE, Neutral, $72.53)Sunday, March 5, 2017 · 10:26 am |
|
Updating My Investment Thinking on Kite (KITE, Neutral, $47.63) and Juno (JUNO, Neutrl, 17.86) in the Aftermath of the ASH MeetingWednesday, December 14, 2016 · 8:26 am |
|
My Current Investment Thinking on Kite (KITE, Neutral, $50.02) and Juno (JUNO, Neutral, $20.14) and the CAR-T Space as a WholeFriday, December 2, 2016 · 9:57 am |
|
Kite Pharma: Highlights of October 18, 2016 Analysts' Day- I Remain More Cautious on the Stock than Mainstream Wall Street Analysts (KITE, Neutral, $46.45)Wednesday, October 19, 2016 · 2:12 pm |
|
Kite Pharma: Interpretation of Results from the Interim Look at ZUMA-1 (KITE, Neutral, $60.25)Tuesday, September 27, 2016 · 9:46 am |
|
Kite Pharma Part 5: Detailed Research That I Have Done In Coming to My Opinion on Kite (KITE, Neutral, $$54.06)Monday, September 26, 2016 · 12:34 pm |
|
Kite Pharma Part 4: A Preview of Highly Anticipated Results from Interim Look at ZUMA-1 (KITE, Neutral, $54.95)Thursday, September 22, 2016 · 3:44 pm |
|
Kite Pharma Part 3: A Detailed Analysis of the Design of the All-Important ZUMA-1 TrialWednesday, September 21, 2016 · 10:17 am |
|
Kite Pharma Part 2: An Overview of CAR-T Cell Drug Development EffortsTuesday, September 20, 2016 · 12:46 pm |
|
Kite Pharma: Part 1- Glossary of Terms and AcronymsTuesday, September 20, 2016 · 12:28 pm |
|
A Non-Consensus, More Balanced Look at the CAR-T Development Efforts of Kite and Juno (Kite, $48.53: Juno, $30.42)Wednesday, July 13, 2016 · 4:44 pm |
|
CAR-T Companies-Kite (KITE, $55.09) and Juno (JUNO, $47.30): Is The Bloom Coming Off The Rose? Are Investor Expectations Unrealistic?Wednesday, April 29, 2015 · 8:57 am |
|
|
There are 15 reports on file. |
